Search Results
Apr 13, 2026, 00:01 ET RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially
More news about: The Schall Law Firm
Apr 10, 2026, 11:23 ET RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Apr 09, 2026, 16:20 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for March 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $93.1 billion as of March 31, 2026, a decrease of $5.3 billion from assets under management of
More news about: Cohen & Steers, Inc.
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Apr 09, 2026, 07:45 ET Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
combination with other CNS depressants, isassociated with CNS adverse reactions, including seizure, respiratory depression,decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and
More news about: Jazz Pharmaceuticals plc
Apr 09, 2026, 07:30 ET Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
central nervous system (CNS).Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary formulation of Aramchol which targets the brain. By crossing the BBB, this new Aramchol formulation could become a disease modifying therapy for unmet chronic CNS diseases.Stearoyl-CoA
More news about: Galmed Pharmaceuticals Ltd.
Apr 09, 2026, 06:30 ET Immunic to Participate in Scientific and Medical Conferences in April
Ph.D., Chief Scientific Officer of ImmunicSession Title: Beyond Microglia: Unlocking New Neuroimmune Targets To Drive Innovation In CNS Drug DiscoverySession Date: Thursday, April 16, 2026Session Time: 12:00 pm ETApril
More news about: Immunic, Inc.
Apr 08, 2026, 16:20 ET Cohen & Steers, Inc. to Release First Quarter 2026 Results on April 16, 2026
NEW YORK, April 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2026 results after the market closes on Thursday, April 16, 2026. The earnings release and accompanying
More news about: Cohen & Steers, Inc.
Apr 08, 2026, 06:56 ET LG Chairman Kwang Mo Koo Visits Silicon Valley to Accelerate AI Transformation and Physical AI Strategy
LG CNS plans to develop an industrial AI humanoid robot solution based on Skild AI's robotic foundation model, optimized with industrial data from manufacturing and logistics to support tasks that conventional robots struggle to perform.Going forward, LG CNS aims
More news about: LG
Apr 08, 2026, 02:02 ET LG CNS、Japan IT Weekに参加 日本における金融DX事業を本格化
https://www.prnewswire.com/jp/news-releases/lg-cnsjapan-it-week-dx-302736645.htmlSOURCE LG CNS
More news about: LG CNS
Apr 07, 2026, 09:00 ET RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Apr 07, 2026, 08:40 ET NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease
sclerosis, and other CNS disorders. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is a leader in developing novel therapeutics that modulate microglial activity, impacting the expression of proteins that drive inflammation in the CNS, thereby improving
More news about: NeuroTherapia, Inc.
Apr 07, 2026, 07:30 ET Allucent Expands Strategic Leadership to Advance Centers of Expertise and Fortify Specialty CRO Position
regulatory approvals.Roberta Anderson joins as therapeutic strategy head, neuroscience, with nearly 30 years of CNS clinical development experience across multiple indications and a strong track record guiding programs through complex regulatory pathways, including
More news about: Allucent
Apr 07, 2026, 06:30 ET Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Apr 06, 2026, 08:04 ET SK Life Science, Inc. to Present New Data and Epilepsy Insights at the 2026 American Academy of Neurology Annual Meeting
pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with 12 compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content
More news about: SK Life Science, Inc.
Apr 06, 2026, 04:04 ET RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially
More news about: The Schall Law Firm
Apr 04, 2026, 07:56 ET RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Apr 03, 2026, 15:19 ET REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights
Plaintiff alleges that in truth, defendants were aware of the serious safety issues relating to the RGX-111 study including the potential for CNS neoplasm and in November 2023 abruptly decided to de-prioritize its second-most advanced clinical candidate, RGX-111, and seek "strategic alternatives"
More news about: Robbins LLP
Apr 02, 2026, 23:11 ET Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Apr 02, 2026, 13:30 ET Perceptive Discovery Expands In Vitro Capabilities at Needham, MA Site to Accelerate Preclinical Oncology Research
translational solutions that bridge scientific innovation to early-phase clinical success. With deep expertise in radiochemistry, in vivo imaging, oncology and CNS models, dosimetry, assay development, and radioligand therapy, Perceptive Discovery provides integrated workflows that generate high-quality, decision-ready
More news about: Perceptive Discovery
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Apr 02, 2026, 09:00 ET Make Time Wellness Names Renowned Psychologist Nicole Beurkens, PhD as Scientific Advisor
maketimewellness.com.About Nicole Beurkens, PhD, CNSDr. Nicole Beurkens is a licensed psychologist, Board-Certified Nutrition Specialist (CNS), and one of the leading experts at the intersection of brain health, nutrition, and mental wellness
More news about: Make Time Wellness
Apr 02, 2026, 07:00 ET Corero Network Security Finds Most DDoS Attacks Now Evade Traditional Defenses as AI Drives Faster, Multi-Vector Threats
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability, today released its 2026 Threat Intelligence Report, revealing a fundamental
More news about: Corero Network Security
Apr 01, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:February 9, 2022: Announced "no drug-related serious
More news about: Levi & Korsinsky, LLP
Apr 01, 2026, 08:30 ET Leverage Cognitive Data to Improve Sleep-Wakefulness Drug Evaluation, Upcoming Webinar Hosted by Xtalks
April 1, 2026 /PRNewswire/ -- Disruption to normal sleep/wake cycles, whether by disease, disorders, injuries of the central nervous system (CNS) or by the drugs used to treat these, can result in substantial disability and increased morbidity and mortality.
More news about: Xtalks